With Pancreaze, a drug for cystic fibrosis patients, Vivus is stepping into an unfamiliar market. So earlier this month, it sponsored a fundraising event to get its name out.
Bristol-Myers Squibb Company and Nordic Bioscience have announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis (NASH).
AbbVie has received a positive opinion for a shorter, eight-week treatment of VIEKIRAX (ombitasvir / paritaprevir / ritonavir tablets) + EXVIERA (dasabuvir tablets).